The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC).

OncoTargets and Therapy
Kui-Feng HeLi-Song Teng

Abstract

Significant progression has been achieved in the treatment of metastatic colorectal cancer (mCRC) in recent years. This has been partly attributed to successfully incorporating new drugs into combination chemotherapy. In addition to the traditional cytotoxic chemotherapeutic agents, molecularly targeted agents began to play an important role in the treatment of advanced solid tumors. To date, two classes of molecularly targeted agents have been approved for treatment of patients with mCRC: (1) antivascular endothelial growth factor (anti-VEGF) agents (such as bevacizumab and aflibercept) and (2) antiendothelial cell growth factor receptor (anti-EGFR) agents (such as cetuximab and panitumumab). Aflibercept is a new member of anti-VEGF agents which has demonstrated efficacy for treatment of mCRC. With the commencement of clinical trials and basic research into aflibercept, more data from the bedside and the bench have been obtained. This review will outline the application of anti-VEGF agents by reviewing clinic experiences of bevacizumab and aflibercept, and try to add perspectives on the use of anti-VEGF agents in mCRC.

References

Mar 24, 1998·Annual Review of Medicine·B R Zetter
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jocelyn HolashJohn S Rudge
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Eugene S KimDarrell J Yamashiro
Jun 5, 2003·Nature Reviews. Cancer·Gabriele Bergers, Laura E Benjamin
Apr 2, 2004·The Journal of Clinical Investigation·Claus CursiefenJ Wayne Streilein
May 12, 2004·Nature Reviews. Drug Discovery·Napoleone FerraraWilliam Novotny
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jun 5, 2004·The Oncologist·Napoleone Ferrara
Oct 12, 2004·Hematology/oncology Clinics of North America·Lee M Ellis
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarSomnath Sarkar
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Limin HuRobert B Jaffe
Oct 31, 2006·Expert Review of Anticancer Therapy·Alfredo CarratoCarmen Guillen-Ponce
Jan 4, 2007·The American Journal of Pathology·Balázs DömeJózsef Tímár
Jan 9, 2007·Journal of Pediatric Surgery·Judah Folkman
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·John S RudgeGeorge D Yancopoulos
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 19, 2008·Biochemistry. Biokhimii︠a︡·A F Karamysheva
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyMark Kozloff
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtRafael G Amado
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
Jun 27, 2009·Onkologie·Werner Scheithauer, Wolff Schmiegel
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Craig LockhartWilliam P Tew
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzJohn V Heymach
Dec 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William P TewDavid R Spriggs
Aug 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Ketao JinLisong Teng
Sep 30, 2010·Journal of the Chinese Medical Association : JCMA·Li-Song TengJiang Cao
Dec 21, 2010·Cancer Chemotherapy and Pharmacology·Satoshi MatsusakaKiyohiko Hatake
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John F de GrootPatrick Y Wen
Oct 18, 2011·Inflammation & Allergy Drug Targets·Michael W Stewart

❮ Previous
Next ❯

Citations

May 16, 2013·Cancer Chemotherapy and Pharmacology·Hoai-Thu ThaiEmmanuelle Comets
Oct 19, 2012·Current Allergy and Asthma Reports·Norbert Meyer, Cezmi A Akdis
Oct 29, 2014·Case Reports in Ophthalmological Medicine·O'Sam ShibeebTimothy Gray

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Software Mentioned

VELOUR
BRiTE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.